507 related articles for article (PubMed ID: 25429378)
1. Noninvasive characterization of graft steatosis after liver transplantation.
Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
[TBL] [Abstract][Full Text] [Related]
2. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
4. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
PLoS One; 2015; 10(11):e0143429. PubMed ID: 26599080
[TBL] [Abstract][Full Text] [Related]
5. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
6. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
[TBL] [Abstract][Full Text] [Related]
7. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?
Machado CM; Leite NC; França PH; Cardoso CR; Salles GF; Villela-Nogueira CA
Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):965-971. PubMed ID: 31377187
[TBL] [Abstract][Full Text] [Related]
8. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
[TBL] [Abstract][Full Text] [Related]
9. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
[TBL] [Abstract][Full Text] [Related]
10. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
[TBL] [Abstract][Full Text] [Related]
11. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.
Petta S; Grimaudo S; Cammà C; Cabibi D; Di Marco V; Licata G; Pipitone RM; Craxì A
J Hepatol; 2012 Jun; 56(6):1356-62. PubMed ID: 22314430
[TBL] [Abstract][Full Text] [Related]
12. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
14. APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases.
Zhang RN; Zheng RD; Mi YQ; Zhou D; Shen F; Chen GY; Zhu CY; Pan Q; Fan JG
Dig Dis Sci; 2016 Aug; 61(8):2284-2293. PubMed ID: 27059980
[TBL] [Abstract][Full Text] [Related]
15. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study.
Trunečka P; Míková I; Dlouhá D; Hubáček JA; Honsová E; Kolesár L; Lánská V; Fraňková S; Šperl J; Jirsa M; Poledne R
Dig Liver Dis; 2018 May; 50(5):490-495. PubMed ID: 29396131
[TBL] [Abstract][Full Text] [Related]
16. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
17. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
[TBL] [Abstract][Full Text] [Related]
18. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
[TBL] [Abstract][Full Text] [Related]
19. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
[TBL] [Abstract][Full Text] [Related]
20. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver.
Alam S; Islam MS; Islam S; Mustafa G; Saleh AA; Ahmad N
Indian J Gastroenterol; 2017 Sep; 36(5):366-372. PubMed ID: 28975533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
